tiprankstipranks
In this article:
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agile Therapeutics (AGRX), Argenx Se (ARGX) and Liminal BioSciences (LMNL)

In this article:
In this article:

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRXResearch Report), Argenx Se (ARGXResearch Report) and Liminal BioSciences (LMNLResearch Report).

Agile Therapeutics (AGRX)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $2.50. The company’s shares closed last Wednesday at $0.34, close to its 52-week low of $0.34.

According to TipRanks.com, Livnat is a 1-star analyst with an average return of -0.2% and a 40.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Zynerba Pharmaceuticals.

Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $2.83.

See Insiders’ Hot Stocks on TipRanks >>

Argenx Se (ARGX)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Argenx Se, with a price target of $400.00. The company’s shares closed last Wednesday at $278.72.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.5% and a 39.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $380.69 average price target, which is a 33.9% upside from current levels. In a report issued on January 7, Piper Sandler also maintained a Buy rating on the stock with a $375.00 price target.

Liminal BioSciences (LMNL)

In a report released today, Edwin Zhang from H.C. Wainwright reiterated a Hold rating on Liminal BioSciences. The company’s shares closed last Wednesday at $1.10, close to its 52-week low of $0.88.

According to TipRanks.com, Zhang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -31.9% and a 9.7% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Calliditas Therapeutics, and Logicbio Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Liminal BioSciences.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AGRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed